Last $6.45 USD
Change Today -0.3499 / -5.15%
Volume 65.2K
As of 8:04 PM 04/16/14 All times are local (Market data is delayed by at least 15 minutes).

medgenics inc - unrestricted (MDGN) Snapshot

Open
$6.78
Previous Close
$6.80
Day High
$6.79
Day Low
$6.41
52 Week High
02/12/14 - $9.00
52 Week Low
06/24/13 - $3.50
Market Cap
116.1M
Average Volume 10 Days
47.8K
EPS TTM
--
Shares Outstanding
18.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDGENICS INC - UNRESTRICTED (MDGN)

Related News

No related news articles were found.

medgenics inc - unrestricted (MDGN) Related Businessweek News

No Related Businessweek News Found

medgenics inc - unrestricted (MDGN) Details

Medgenics, Inc., a medical technology and therapeutics company, is engaged in the research and development of products in the field of biotechnology and associated medical equipment in the United States. The company develops and commercializes Biopump platform technology that converts a piece of the patient’s own dermal skin tissue into a protein- and/or peptide-producing ‘Biopump’ to produce and deliver therapeutic proteins and/or peptides, and—when implanted under the patient’s skin—has the potential to deliver various months of protein/peptide therapy. Its product candidates include EPODURE Biopump, which is in Phase I/II clinical trials for the treatment of anemia in CKD and renal failure; and HEMODURE Biopump, which is under pre-clinical studies and produces Factor VIII for the treatment of patients with hemophilia. The company also develops INFRADURE Biopump that produces interferon-alpha for the treatment of patients with hepatitis C. Medgenics, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.

36 Employees
Last Reported Date: 02/20/14
Founded in 2000

medgenics inc - unrestricted (MDGN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $226.1K
Chief Financial Officer
Total Annual Compensation: $216.2K
Global Head of Research and Development
Total Annual Compensation: $193.9K
Principal Accounting Officer, Vice President ...
Total Annual Compensation: $175.0K
Compensation as of Fiscal Year 2013.

medgenics inc - unrestricted (MDGN) Key Developments

Medgenics, Inc. Announces Retirement of Andrew L. Pearlman from the Board of Directors

Medgenics, Inc. announced that Andrew L. Pearlman retired from the Board of Directors at the Annual Meeting of Stockholders held on April 8, 2014.

Medgenics, Inc. Approves Cancellation Of Common Stock Shares From Trading On London Stock Exchange's Alternative Investment Market

Medgenics, Inc. announced that the resolutions proposed at the company's annual meeting of stockholders held on April 8, 2014 was duly passed. Stockholders approved the cancellation of the company's common stock shares from trading on the London Stock Exchange's Alternative Investment Market, or AIM. The last day of trading of the company's common stock on AIM is expected to be April 15, 2014.

Medgenics, Inc., Annual General Meeting, Apr 08, 2014

Medgenics, Inc., Annual General Meeting, Apr 08, 2014., at 10:00 US Eastern Standard Time. Location: Duane Morris LLP. Agenda: To elect nine persons to serve on Board of Directors until the next annual meeting of stockholders and until their respective successors are duly elected and qualified; to approve the cancellation of the admission of shares of common stock to trading on the London Stock Exchange's Alternative Investment Market ("AIM"); to approve an amendment to the Medgenics, Inc. Stock Incentive Plan to increase the number of shares reserved for issuance thereunder; to ratify the appointment of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as independent registered public accounting firm for the fiscal year ending December 31, 2014; and to transact such other proper business as may come before the meeting and any adjournment or postponement of the meeting.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDGN:US $6.45 USD -0.3499

MDGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MDGN.
View Industry Companies
 

Industry Analysis

MDGN

Industry Average

Valuation MDGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 6.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDGENICS INC - UNRESTRICTED, please visit www.medgenics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.